These preexisting conditions in lung cancer patients may result in heightened inflammation and diminish adaptive immune responses upon SARS‐CoV‐2 infection, highlighting the critical role of TMPRSS2 in immune modulation. The gene discussed is TMPRSS2; the disease is lung cancer.